The  ||| S:0 E:4 ||| DT
process  ||| S:4 E:12 ||| NN
of  ||| S:12 E:15 ||| IN
NCCN  ||| S:15 E:20 ||| NNP
guidelines  ||| S:20 E:31 ||| NNS
adaptation  ||| S:31 E:42 ||| VBP
to  ||| S:42 E:45 ||| TO
the  ||| S:45 E:49 ||| DT
Middle  ||| S:49 E:56 ||| NNP
East  ||| S:56 E:61 ||| NNP
and  ||| S:61 E:65 ||| CC
North  ||| S:65 E:71 ||| NNP
Africa  ||| S:71 E:78 ||| NNP
region  ||| S:78 E:85 ||| NN
The  ||| S:85 E:89 ||| DT
NCCN  ||| S:89 E:94 ||| NNP
developed  ||| S:94 E:104 ||| VBD
clinical  ||| S:104 E:113 ||| JJ
practice  ||| S:113 E:122 ||| NN
guidelines  ||| S:122 E:133 ||| NNS
for  ||| S:133 E:137 ||| IN
oncology  ||| S:137 E:146 ||| NNS
that  ||| S:146 E:151 ||| WDT
set  ||| S:151 E:155 ||| VBD
the  ||| S:155 E:159 ||| DT
standard  ||| S:159 E:168 ||| NN
of  ||| S:168 E:171 ||| IN
cancer  ||| S:171 E:178 ||| NN
care  ||| S:178 E:183 ||| NN
in  ||| S:183 E:186 ||| IN
the  ||| S:186 E:190 ||| DT
United  ||| S:190 E:197 ||| NNP
States ||| S:197 E:203 ||| NNPS
.  ||| S:203 E:205 ||| .
Because  ||| S:205 E:213 ||| IN
of  ||| S:213 E:216 ||| IN
wide  ||| S:216 E:221 ||| JJ
acceptance  ||| S:221 E:232 ||| NN
of ||| S:232 E:234 ||| IN
,  ||| S:234 E:236 ||| ,
need  ||| S:236 E:241 ||| VBP
for ||| S:241 E:244 ||| IN
,  ||| S:244 E:246 ||| ,
and  ||| S:246 E:250 ||| CC
interest  ||| S:250 E:259 ||| NN
in  ||| S:259 E:262 ||| IN
standardized  ||| S:262 E:275 ||| JJ
treatment  ||| S:275 E:285 ||| NN
practices  ||| S:285 E:295 ||| NNS
across  ||| S:295 E:302 ||| IN
the  ||| S:302 E:306 ||| DT
world ||| S:306 E:311 ||| NN
,  ||| S:311 E:313 ||| ,
NCCN  ||| S:313 E:318 ||| NNP
launched  ||| S:318 E:327 ||| VBD
initiatives  ||| S:327 E:339 ||| NNS
to  ||| S:339 E:342 ||| TO
help  ||| S:342 E:347 ||| VB
international  ||| S:347 E:361 ||| JJ
groups  ||| S:361 E:368 ||| NNS
adapt  ||| S:368 E:374 ||| VBP
these  ||| S:374 E:380 ||| DT
guidelines ||| S:380 E:390 ||| NNS
.  ||| S:390 E:392 ||| .
This  ||| S:392 E:397 ||| DT
article  ||| S:397 E:405 ||| NN
describes  ||| S:405 E:415 ||| VBZ
the  ||| S:415 E:419 ||| DT
initiative  ||| S:419 E:430 ||| NN
in  ||| S:430 E:433 ||| IN
the  ||| S:433 E:437 ||| DT
Middle  ||| S:437 E:444 ||| NNP
East  ||| S:444 E:449 ||| NNP
and  ||| S:449 E:453 ||| CC
North  ||| S:453 E:459 ||| NNP
Africa  ||| S:459 E:466 ||| NNP
( ||| S:466 E:467 ||| -LRB-
MENA ||| S:467 E:471 ||| NNP
)  ||| S:471 E:473 ||| -RRB-
region ||| S:473 E:479 ||| NN
.  ||| S:479 E:481 ||| .
A  ||| S:481 E:483 ||| DT
group  ||| S:483 E:489 ||| NN
of  ||| S:489 E:492 ||| IN
oncology  ||| S:492 E:501 ||| JJ
experts  ||| S:501 E:509 ||| NNS
and  ||| S:509 E:513 ||| CC
key  ||| S:513 E:517 ||| JJ
opinion  ||| S:517 E:525 ||| NN
leaders  ||| S:525 E:533 ||| NNS
were  ||| S:533 E:538 ||| VBD
assembled  ||| S:538 E:548 ||| VBN
into  ||| S:548 E:553 ||| IN
7  ||| S:553 E:555 ||| CD
specific  ||| S:555 E:564 ||| JJ
committees  ||| S:564 E:575 ||| NNS
to  ||| S:575 E:578 ||| TO
develop  ||| S:578 E:586 ||| VB
treatment  ||| S:586 E:596 ||| NN
guidelines  ||| S:596 E:607 ||| NNS
for  ||| S:607 E:611 ||| IN
breast  ||| S:611 E:618 ||| JJ
cancer ||| S:618 E:624 ||| NN
,  ||| S:624 E:626 ||| ,
lung  ||| S:626 E:631 ||| NN
cancer ||| S:631 E:637 ||| NN
,  ||| S:637 E:639 ||| ,
colon  ||| S:639 E:645 ||| NN
cancer ||| S:645 E:651 ||| NN
,  ||| S:651 E:653 ||| ,
prostate  ||| S:653 E:662 ||| JJ
cancer ||| S:662 E:668 ||| NN
,  ||| S:668 E:670 ||| ,
hepatobiliary  ||| S:670 E:684 ||| JJ
cancer ||| S:684 E:690 ||| NN
,  ||| S:690 E:692 ||| ,
lymphoma ||| S:692 E:700 ||| NN
,  ||| S:700 E:702 ||| ,
and  ||| S:702 E:706 ||| CC
palliative  ||| S:706 E:717 ||| JJ
care ||| S:717 E:721 ||| NN
.  ||| S:721 E:723 ||| .
The  ||| S:723 E:727 ||| DT
committees  ||| S:727 E:738 ||| NNS
reviewed  ||| S:738 E:747 ||| VBN
the  ||| S:747 E:751 ||| DT
NCCN  ||| S:751 E:756 ||| NNP
Clinical  ||| S:756 E:765 ||| NNP
Practice  ||| S:765 E:774 ||| NNP
Guidelines  ||| S:774 E:785 ||| NNP
in  ||| S:785 E:788 ||| IN
Oncology  ||| S:788 E:797 ||| NNP
( ||| S:797 E:798 ||| -LRB-
NCCN  ||| S:798 E:803 ||| NNP
Guidelines ||| S:803 E:813 ||| NNP
)  ||| S:813 E:815 ||| -RRB-
to  ||| S:815 E:818 ||| TO
identify  ||| S:818 E:827 ||| VB
any  ||| S:827 E:831 ||| DT
modifications  ||| S:831 E:845 ||| NNS
required  ||| S:845 E:854 ||| VBN
for  ||| S:854 E:858 ||| IN
them  ||| S:858 E:863 ||| PRP
to  ||| S:863 E:866 ||| TO
be  ||| S:866 E:869 ||| VB
more  ||| S:869 E:874 ||| RBR
applicable  ||| S:874 E:885 ||| JJ
to  ||| S:885 E:888 ||| TO
the  ||| S:888 E:892 ||| DT
MENA  ||| S:892 E:897 ||| NNP
region  ||| S:897 E:904 ||| NN
based  ||| S:904 E:910 ||| VBN
on  ||| S:910 E:913 ||| IN
available  ||| S:913 E:923 ||| JJ
evidence  ||| S:923 E:932 ||| NN
and  ||| S:932 E:936 ||| CC
regional  ||| S:936 E:945 ||| JJ
experience ||| S:945 E:955 ||| NN
.  ||| S:955 E:957 ||| .
These  ||| S:957 E:963 ||| DT
modifications  ||| S:963 E:977 ||| NNS
were  ||| S:977 E:982 ||| VBD
discussed  ||| S:982 E:992 ||| VBN
with  ||| S:992 E:997 ||| IN
NCCN  ||| S:997 E:1002 ||| NNP
experts  ||| S:1002 E:1010 ||| NNS
and  ||| S:1010 E:1014 ||| CC
summarized  ||| S:1014 E:1025 ||| NN
for  ||| S:1025 E:1029 ||| IN
each  ||| S:1029 E:1034 ||| DT
specific  ||| S:1034 E:1043 ||| JJ
area ||| S:1043 E:1047 ||| NN
.  ||| S:1047 E:1049 ||| .
The  ||| S:1049 E:1053 ||| DT
development  ||| S:1053 E:1065 ||| NN
of  ||| S:1065 E:1068 ||| IN
these  ||| S:1068 E:1074 ||| DT
guidelines  ||| S:1074 E:1085 ||| NNS
generated  ||| S:1085 E:1095 ||| VBD
a  ||| S:1095 E:1097 ||| DT
strong  ||| S:1097 E:1104 ||| JJ
interest  ||| S:1104 E:1113 ||| NN
in  ||| S:1113 E:1116 ||| IN
the  ||| S:1116 E:1120 ||| DT
region  ||| S:1120 E:1127 ||| NN
to  ||| S:1127 E:1130 ||| TO
develop  ||| S:1130 E:1138 ||| VB
more  ||| S:1138 E:1143 ||| RBR
evidence-based  ||| S:1143 E:1158 ||| JJ
practice  ||| S:1158 E:1167 ||| NN
and  ||| S:1167 E:1171 ||| CC
create  ||| S:1171 E:1178 ||| VB
further  ||| S:1178 E:1186 ||| JJ
networking  ||| S:1186 E:1197 ||| NN
and  ||| S:1197 E:1201 ||| CC
collaboration ||| S:1201 E:1214 ||| NN
.  ||| S:1214 E:1216 ||| .
